Acquired Hemophilia Treatment Market Analysis, Share And Growth 2025 To 2034

For organizations targeting expansion, this report delivers actionable intelligence on how the acquired hemophilia treatment industry is evolving.

How Large Will The Acquired Hemophilia Treatment Market Be By 2025?
The acquired hemophilia treatment market size has grown strongly in recent years. It will grow from $12.2 billion in 2024 to $12.83 billion in 2025 at a compound annual growth rate (CAGR) of 5.2%. The growth in the historic period can be attributed to increasing ageing population, improved diagnostics and awareness, expanding patient pool, collaborative research initiatives, regulatory support and approvals.

The acquired hemophilia treatment market size is expected to see steady growth in the next few years. It will grow to $15.24 billion in 2029 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed to growing global population, rising healthcare investments, personalized medicine trends, international collaborations in research, increasing healthcare awareness, regulatory support for orphan drugs. Major trends in the forecast period include enhanced monitoring and diagnostic technologies, collaboration for patient support programs, research on gene therapy approaches, increased utilization of immune tolerance induction, telemedicine for remote consultations.

Get your free sample today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13363&type=smp

What Are Key Factors Driving The Demand In The Global Acquired Hemophilia Treatment Market?
A growing number of ongoing clinical trials is expected to propel the growth of the acquired hemophilia treatment market going forward. Clinical trials are research studies conducted with human participants to evaluate the safety and effectiveness of new medical treatments, interventions, or diagnostic procedures. Clinical trials assess the safety and efficacy of new treatments for acquired hemophilia, advancing research to improve patient outcomes and establish effective therapeutic interventions. For instance, in October 2023, according to ClinicalTrials.gov, a part of the National Institutes of Health (NIH), a US-based government agency responsible for conducting and supporting medical research, the number of registered studies increased from 437,523 in 2022 to 468,457 in all 50 states of the United States and across 221 countries. Moreover, it was reported that 143,613 studies (31% of the total) are registered in the U.S. only, while 251,159 studies (54% of the total) are registered in non-U.S. locations. Therefore, a growing number of ongoing clinical trials is driving the growth of the acquired hemophilia treatment market.

Comparative Analysis Of Leading Acquired Hemophilia Treatment Market Segments
The acquired hemophilia treatmentmarket covered in this report is segmented –

1) By Treatment: On-Demand; Prophylaxis
2) By Type: Hemophilia A; Hemophilia B; Hemophilia C; Other Types
3) By End User: Hospitals; Clinic; Other End Users

Subsegments:
1) By On-Demand: Clotting Factor Replacement Therapy; Desmopressin; Other On-Demand Treatments
2) By Prophylaxis: Clotting Factor Replacement Therapy; Gene Therapy; Other Prophylaxis Treatments

What Are The Key Trends Shaping The Acquired Hemophilia Treatment Industry?
Major companies operating in the acquired hemophilia treatment market are focused on providing drugs with additional measures and getting them approved to sustain their position in the market. Drug approvals to include routine prophylaxis are increasing, mainly due to the need for more effective and safer. For instance, in June 2022, Chugai Pharmaceutical, a Japan-based drug manufacturer received extended approval from Japan’s Ministry of Health, Labor and Welfare, to expand its use of Hemlibra (emicizumab) to include routine prophylaxis measures aimed at reducing or minimizing the occurrence of bleeds in individuals with acquired hemophilia A. Following this approval, additional measures to promptly manage and control bleeding shortly after diagnosis were allowed using Hemlibra, a bispecific antibody that binds simultaneously to two key targets, factor IX and factor X binding sites in the blood clotting process.

Who Are The Prominent Players In The Acquired Hemophilia Treatment Business?
Major companies operating in the acquired hemophilia treatment market report are Pfizer Inc., Roche Holding AG, Bayer AG, Novartis AG, Bristol-Myers Squibb Company, Sanofi SA, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Amgen Inc., Novo Nordisk A/S, Baxter Healthcare Corporation, Teva Pharmaceutical Industries Ltd., Mylan NV, Biogen Inc., CSL Limited, Grifols SA, Genentech Inc., Octapharma AG, Ferring Pharmaceuticals BV, Shire PLC, BioMarin Pharmaceutical Inc., Sobi Inc., Kedrion Biopharma Inc., Chugai Pharmaceutical Co. Ltd., Spark Therapeutics Inc., Medexus Pharmaceuticals Inc., UniQure NV, Catalyst Biosciences Inc., Hema Biologics LLC, BioXcel Corporation

View the full acquired hemophilia treatment market report here:
https://www.thebusinessresearchcompany.com/report/acquired-hemophilia-treatment-global-market-report

Which Region Is Expected To Lead The Acquired Hemophilia Treatment Market By 2025?
North America was the largest region in the acquired hemophilia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acquired hemophilia treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:

The Business Research Company

https://thebusinessresearchcompany.com/

Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267

Email: info@tbrc.info


Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company